Answer
Emtricitabine/Rilpivirine/Tenofovir Disoproxil Gilead is not recommended for moderate or severe renal impairment (creatinine clearance below 50 mL/min), because the required dose-interval adjustments for emtricitabine and tenofovir disoproxil cannot be achieved with the combination tablet.
Sources for this answer
- Emtricitabine/Rilpivirine/Tenofovir Disoproxil Gilead 200 mg/25 mg/245 mg film coated tabletsGilead Sciences Ltd · emc · SmPC §4.2 Posology and method of administration · Version 33Document updated
Sources checked